FDA Enters New Enforcement Territory With Warnings Against Failed NDIs
This article was originally published in The Tan Sheet
Executive Summary
Recent warnings about aromatase inhibitors fraudulently marketed as dietary supplements mark a shift in FDA's enforcement against what the agency says is a growing problem of spiked nutritionals